Theravance Inc. (THRX) and GlaxoSmithKline (GSK) announced late Wednesday afternoon that the Pulmonary-Allergy Drugs Advisory Committee of the FDA voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA.
Theravance has gapped open sharply higher Thursday and is now up 4.41 at $32.42. The stock has broken out to a new high for the year.
For comments and feedback: editorial@rttnews.com